Neurocrine Biosciences (NBIX) free cash flow

Free cash flow · fiscal 2025
$748.70M

Neurocrine Biosciences (NBIX) generated free cash flow of $748.70M in fiscal 2025 (the year ended December 31, 2025). That is 34.4% higher than the $557.20M of fiscal 2024. Figures as of 18 Nov 2026, 12:41 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$748.70M
Change on fiscal 2024
+34.4%
Growth, 5 years
+28.0% a year
Highest on record
$748.70Mfiscal 2025
Lowest on record
-$110.29Mfiscal 2016
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Neurocrine Biosciences free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow grew at a compound 28.0% a year. Across the 17 fiscal years on record (2009–2025), the highest was $748.70M in fiscal 2025 and the lowest -$110.29M in fiscal 2016.

History · 17 fiscal years

Free cash flow by fiscal year

Neurocrine Biosciences free cash flow, year by year

Neurocrine Biosciences (NBIX) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$748.70M 34.4% up
2024$557.20M 54.1% up
2023$361.60M 12.0% up
2022$322.90M 38.5% up
2021$233.10M 7.1% up
2020$217.60M 64.5% up
2019$132.30M 72.7% up
2018$76.60M—
2017-$101.27M—
2016-$110.29M—
2015-$39.93M—
2014-$48.75M—
2013-$30.15M—
2012-$36.27M—
2011-$1.45M 102.9% down
2010$49.63M—
2009-$53.13M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Neurocrine Biosciences and comparable companies
CompanyFree cash flowFiscal year
Revvity RVTY$509.41M2025
Exelixis EXEL$844.34M2025
Charles River Laboratories International CRL$518.49M2025
Neurocrine Biosciences NBIX$748.70M2025
Ascendis Pharma ASND€45.41M2025
ICON ICLR$861.99M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on NBIX

Neurocrine Biosciences, figure by figure

Neurocrine Biosciences (NBIX) overview: price, valuation and scorecardAll health care companies by market value

Neurocrine Biosciences free cash flow: questions and answers

What is Neurocrine Biosciences's free cash flow?

Neurocrine Biosciences (NBIX) generated free cash flow of $748.70M in fiscal 2025 (the year ended December 31, 2025). That is 34.4% higher than the $557.20M of fiscal 2024.

What is the growth rate of Neurocrine Biosciences's free cash flow?

Over the five fiscal years to 2025 free cash flow grew at a compound 28.0% a year.

What are the highest and lowest free cash flow figures on record for Neurocrine Biosciences?

Across the 17 fiscal years on record (2009–2025), the highest was $748.70M in fiscal 2025 and the lowest -$110.29M in fiscal 2016.

How is Neurocrine Biosciences's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Neurocrine Biosciences it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Neurocrine Biosciences (NBIX) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/NBIX/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.